下肢深静脉血栓形成及其伴发的致命性肺栓塞是常见的临床急症，下腔静脉滤器置入是挽救此类患者的重要治疗方案，大大降低病死率。但是滤器置入相关血管并发症、再次手术取出的痛苦和经济负担始终困扰着临床医生，成为制约这一病症长期效果的核心。因此研发完全生物可降解滤器，急性期发挥滤栓作用后被机体完全降解吸收无疑是一项十分有临床价值的探索，之前有学者开展了相关研究，受限于材料功能不足，均未取得实质性进展。我们利用前期合成的一种生物相容性良好的可降解材料PVDF/ACM，预实验制备了与实验猪下腔静脉匹配的滤器，初步形状记忆和降解性能满意。期望在此基础上探索本材料的形状记忆、力学性能及降解时间窗，同时结合药物洗脱技术表面载入CD144抗体捕获内皮祖细胞保护内皮功能预防血栓，阐释内皮祖细胞洗脱保护内皮功能的机制，最终研发有效的完全生物可降解下腔静脉滤器。

Deep-vein thromboembolism and associated pulmonary embolism are among the most common deadly clinical emergency. Use of inferior vena cava (IVC) filters can significantly decrease the morbidity and mortality. The major complications of current filter technology including occlusion,recurrent deep venous thrombosis, really limit the aggressive use though its promising prophylaxis. A biodegradable filter device would provide the critical protection against pulmonary embolism through the period of highest risk after major surgery or trauma, while avoiding the long-term disadvantages of nowaday devices. Based on our former research of a biodegradable PVDF/ACM and initial in-vivo results, combined with eluting CD144 Ab to provide more endothelial progenitor cell (EPC)locally,we aim to explore the feasibility and efficacy of the filter from the biodegradable material，escaping from lumen stenosis in the vena cava and the possible endothelial protection mechanism from EPC-elution.